These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 3006432)
1. Studies of neurotensin-dopamine receptor interactions in striatal membranes of the male rat. The influence of 6-hydroxydopamine-induced dopamine receptor supersensitivity. Fuxe K; Agnati LF; Martire M; Neumeyer A; Benfenati F; Frey P Acta Physiol Scand; 1986 Jan; 126(1):147-9. PubMed ID: 3006432 [No Abstract] [Full Text] [Related]
2. Repeated D1 dopamine receptor agonist administration prevents the development of both D1 and D2 striatal receptor supersensitivity following denervation. Hu XT; White FJ Synapse; 1992 Mar; 10(3):206-16. PubMed ID: 1532677 [TBL] [Abstract][Full Text] [Related]
3. Role of opiates in striatal D-1 dopamine receptor supersensitivity induced by chronic L-dopa treatment. Groppetti A; Ceresoli G; Mandelli V; Parenti M J Pharmacol Exp Ther; 1990 Jun; 253(3):950-6. PubMed ID: 2162953 [TBL] [Abstract][Full Text] [Related]
4. Effect of supersensitivity of pre- and postsynaptic dopamine receptors on the activity of endogenous inhibitor of cAMP dependent protein kinase in rat striatum. Szmigielski A; Szadowska A; Szmigielska H Arch Int Pharmacodyn Ther; 1984 Dec; 272(2):214-24. PubMed ID: 6098230 [TBL] [Abstract][Full Text] [Related]
5. Dopamine agonist-induced elevation of striatal acetylcholine: relationship between receptor occupancy and response in normal and denervated rat striatum. Enz A; Goldstein M; Meller E Mol Pharmacol; 1990 Apr; 37(4):560-5. PubMed ID: 1970116 [TBL] [Abstract][Full Text] [Related]
6. In vivo studies of striatal dopamine release and metabolism following administration of L-dopa. Brannan T; Knott P; Kaufmann H; Yahr M Adv Neurol; 1990; 53():75-81. PubMed ID: 2173378 [No Abstract] [Full Text] [Related]
7. D-1 receptor supersensitivity in the rat striatum after unilateral 6-hydroxydopamine lesions. Buonamici M; Caccia C; Carpentieri M; Pegrassi L; Rossi AC; Di Chiara G Eur J Pharmacol; 1986 Jul; 126(3):347-8. PubMed ID: 3093251 [No Abstract] [Full Text] [Related]
8. Evidence for multiple dopamine receptors involved in the modulation of acetylcholine release in the striatum. Hársing LG; Vizi ES Pol J Pharmacol Pharm; 1985; 37(3):383-96. PubMed ID: 2866504 [TBL] [Abstract][Full Text] [Related]
10. Dopamine receptors in the denervated striatum: further supersensitivity by chronic haloperidol treatment. Reches A; Wagner RH; Jackson V; Yablonskaya-Alter E; Fahn S Brain Res; 1983 Sep; 275(1):183-5. PubMed ID: 6414646 [No Abstract] [Full Text] [Related]
11. [Presynaptic autoregulation of dopamine release]. Zharikova AD; Godukhin OV Fiziol Zh SSSR Im I M Sechenova; 1985 Jan; 71(1):105-12. PubMed ID: 2982672 [TBL] [Abstract][Full Text] [Related]
12. Further evidence for the existence of interactions between receptors for dopamine and neurotensin. Dopamine reduces the affinity and increases the number of [3H]-neurotensin binding sites in the subcortical limbic forebrain of the rat. Agnati LF; Fuxe K; Battistini N; Giardino L; Benfenati F; Martire M; Ruggeri M Acta Physiol Scand; 1985 May; 124(1):125-8. PubMed ID: 2990164 [No Abstract] [Full Text] [Related]
15. Fetal substantia nigra grafts. Effect on dopamine receptors in the rat corpus striatium. Korfali E; Knowles WD; Uysal S; Ulus IH; Ozmen T Cleve Clin J Med; 1989 May; 56(3):259-62. PubMed ID: 2568188 [TBL] [Abstract][Full Text] [Related]
16. The effects of nigrostriatal 6-hydroxydopamine lesions on dopamine D2 receptor mRNA and opioid systems. Mansour A; Meador-Woodruff JH; Camp DM; Robinson TE; Bunzow J; Van Tol H; Civelli O; Akil H; Watson SJ Prog Clin Biol Res; 1990; 328():227-30. PubMed ID: 2106148 [No Abstract] [Full Text] [Related]
17. Dopamine receptors: effects of chronic L-dopa and bromocriptine treatment in an animal model of Parkinson's disease. Schneider MB; Murrin LC; Pfeiffer RF; Deupree JD Clin Neuropharmacol; 1984; 7(3):247-57. PubMed ID: 6435870 [TBL] [Abstract][Full Text] [Related]
18. Compensatory mechanisms in the nigrostriatal dopaminergic system in Parkinson's disease: studies in an animal model. Melamed E; Hefti F; Wurtman RJ Isr J Med Sci; 1982 Jan; 18(1):159-63. PubMed ID: 6121770 [TBL] [Abstract][Full Text] [Related]
19. Postsynaptic striatal dopamine agonist or antagonist actions of (+) or (-) 3-PPP and modification after receptor deafferentation. Oberlander C; Boissier JR J Pharmacol; 1983; 14(4):401-4. PubMed ID: 6423905 [TBL] [Abstract][Full Text] [Related]
20. Autoradiographic evidence for the localization of high affinity neurotensin binding sites on dopaminergic nerve terminals in the nigrostriatal and mesolimbic pathways in rat brain. Schotte A; Leysen JE J Chem Neuroanat; 1989; 2(5):253-7. PubMed ID: 2553068 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]